Key result
Surface Modifying Additive (SMA)-treated cardiopulmonary bypass circuits better preserved blood pressure at CPB initiation compared with non-SMA circuits (p <0.05).
Why the study?
Does the use of SMA-treated cardiopulmonary bypass circuits improve blood pressure preservation and modulate renal and cytokine changes in low-risk CABG patients?
RCT (n=40)
randomized
Does the use of SMA-treated cardiopulmonary bypass circuits improve blood pressure preservation and modulate renal and cytokine changes in low-risk CABG patients?
SMA-treated cardiopulmonary bypass circuits may offer clinical benefits such as better blood pressure preservation and reduced blood loss in low-risk CABG patients, particularly those on ACE inhibitors.
Answers are grounded in this paper and cite their sources.
Supports SMA circuits for early BP stability in low-risk CABG; extends biocompatibility evidence for perfusion circuits.
Biocompatible cardiopulmonary bypass (CPB) circuits aim to reduce contact activation and its physiological consequences. We investigated the hypothesis that use of Surface Modifying Additive (SMA)-treated circuits (Sorin Group Ltd) compared with non-SMA circuits would be associated with preservation of blood pressure during CPB and modulation of perioperative subclinical renal function (urinary alpha-1-microglobulin (alpha-1-m)) and plasma and urinary cytokine changes. In a study of low-risk CABG patients (n=40), randomized to SMA (n=20) versus non-SMA circuits (n=20), we found better preserved blood pressure at CPB initiation in SMA patients (p <0.05), particularly in ACE-inhibited SMA patients (n =11) versus ACE-inhibited non-SMA patients (n =10) (p <0.05). Plasma anti-inflammatory IL-10, as well as urinary alpha-1-m, were elevated 48 hours postoperatively (p <0.05). SMA patients also had lower blood loss (p <0.05). SMA circuits have some clinical benefit, especially in ACE-inhibited patients.
No takes yet. Share an insight, caveat, or question.
Allen et al. (2005) conducted an RCT in low-risk CABG (n=40). Surface Modifying Additive (SMA)-treated circuits vs. non-SMA circuits was evaluated on Blood pressure during CPB, perioperative subclinical renal function, and plasma and urinary cytokine changes (p=<0.05). Surface Modifying Additive (SMA)-treated cardiopulmonary bypass circuits better preserved blood pressure at CPB initiation compared with non-SMA circuits (p <0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: